The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ADMA BIOLOGICS INC | COM | 000899104 | 13,964 | 3,608,171 | SH | SOLE | 3,608,171 | 0 | 0 | ||
| AIMMUNE THERAPEUTICS INC. | COM | 00900T107 | 41,432 | 1,990,000 | SH | SOLE | 1,990,000 | 0 | 0 | ||
| CIDARA THERAPEUTICS INC. | COM | 171757107 | 1,716 | 1,021,148 | SH | SOLE | 1,021,148 | 0 | 0 | ||
| TRANSENTERIX INC. | COM NEW | 89366M201 | 3,226 | 2,389,352 | SH | SOLE | 2,389,352 | 0 | 0 | ||